We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ct-inm005-01
Previous Study | Return to List | Next Study

A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04494984
Recruitment Status : Completed
First Posted : July 31, 2020
Last Update Posted : February 11, 2021
Sponsor:
Information provided by (Responsible Party):
Inmunova S.A.

Tracking Information
First Submitted Date  ICMJE July 29, 2020
First Posted Date  ICMJE July 31, 2020
Last Update Posted Date February 11, 2021
Actual Study Start Date  ICMJE July 27, 2020
Actual Primary Completion Date November 23, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 31, 2020)
Clinical changes in COVID-19 symptoms [ Time Frame: 4 weeks ]
The primary endpoint will be the proportion of patients who show a change in symptoms 28 days after the administration of the first dose. A responding subject is defined as a subject with improvement in at least 2 categories on the 8-point World Health Organization (WHO) ordinal scale of clinical status or a subject who is discharged.
Original Primary Outcome Measures  ICMJE
 (submitted: July 30, 2020)
Clinical improvement of COVID-19 symptoms [ Time Frame: 4 weeks ]
The primary endpoint will be the proportion of patients who showed improvement 28 days after the administration of the first dose. A responding subject is defined as a subject with improvement in at least 2 categories on the 8-point WHO ordinal scale of clinical status or a subject who is discharged.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 31, 2020)
  • Pharmacokinetics evaluation of INM005 [ Time Frame: 1 week ]
    INM005 product concentration in serum at different time points after dosing
  • Time to progression of disease [ Time Frame: 4 weeks ]
    Time to achieve a change in at least 2 categories on the 8-point WHO ordinal scale of clinical status. Time to discharge (days). Time to intensive care unit (ICU) discharge (days).
  • Disease progression [ Time Frame: up to 2 weeks ]
    Proportion of patients who present change in at least 2 categories on the 8-point WHO ordinal scale of clinical status at 7 and 14 days after the start of the treatment.
  • Discharge [ Time Frame: up to 4 weeks ]
    Proportion of patients discharged at 28 days
  • Intensive care unit (ICU) hospitalization [ Time Frame: up to 4 weeks ]
    Proportion of patients who require ICU hospitalization
  • Mechanical ventilation assistance (MVA) [ Time Frame: up to 4 weeks ]
    Proportion of patients who require MVA
  • Mortality [ Time Frame: up to 4 weeks ]
    Proportion of patients who die due to complications from COVID19
  • Changes in viral load [ Time Frame: up to 3 weeks ]
    Change in viral load from baseline to 7 and 21 days after the start of the treatment.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 30, 2020)
  • Pharmacokinetics evaluation of INM005 [ Time Frame: 1 week ]
    INM005 product concentration in serum at different time points after dosing
  • Time to progression of disease [ Time Frame: 4 weeks ]
    Time to achieve improvement in at least 2 categories on the 8-point WHO ordinal scale of clinical status. Time to discharge (days). Time to intensive care unit (ICU) discharge (days).
  • Disease progression [ Time Frame: 4 weeks ]
    Proportion of patients who present an improvement in at least 2 categories on the 8-point WHO ordinal scale of clinical status at 7 and 14 days after the start of the treatment. Proportion of patients with discharge at 28 days. Proportion of patients who require ICU hospitalization Proportion of patients who require mechanical ventilation assistance (MVA). Proportion of patients who died.
  • Changes in viral load [ Time Frame: 3 weeks ]
    Change in viral load from baseline to 7 and 21 days after the start of the treatment.
Current Other Pre-specified Outcome Measures
 (submitted: July 31, 2020)
  • Anti SARS-CoV2 antibodies levels [ Time Frame: 3 weeks ]
    Measurement of anti SARS-CoV2 antibodies titer levels. IgG (0, 21 days)
  • Changes in Troponin T levels [ Time Frame: 3 weeks ]
    Changes in Troponin T levels will be evaluated at 7 and 21 days as a measurement of disease progression
  • Changes in D-dimer levels [ Time Frame: 3 weeks ]
    Changes in D-dimer levels will be evaluated at 7 and 21 days as a measurement of disease progression
  • Changes in Ferritin levels [ Time Frame: 3 weeks ]
    Changes in Ferritin levels will be evaluated at 7 and 21 days as a measurement of disease progression
  • Changes in LDH levels [ Time Frame: 3 weeks ]
    Changes in LDH levels will be evaluated at 7 and 21 days as a measurement of disease progression
  • Changes in C-reactive protein levels [ Time Frame: 3 weeks ]
    Changes in C-reactive protein levels will be evaluated at 7 and 21 days as a measurement of disease progression
  • Immunogenicity [ Time Frame: 3 weeks ]
    Measurement of anti-INM005 antibodies: baseline and 21 days
Original Other Pre-specified Outcome Measures
 (submitted: July 30, 2020)
  • Anti SARS-CoV2 antibodies levels [ Time Frame: 3 weeks ]
    Measurement of anti SARS-CoV2 antibodies titer levels. IgG (0, 21 days)
  • Changes in laboratory variables that predict disease progression [ Time Frame: 3 weeks ]
    Evaluable laboratory variables baseline, 7 and 21 days: Troponin T, D-dimer, ferritin, LDH, C-reactive protein
  • Immunogenicity [ Time Frame: 3 weeks ]
    Measurement of anti-INM005 antibodies: baseline and 21 days
 
Descriptive Information
Brief Title  ICMJE A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
Official Title  ICMJE A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.
Brief Summary This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV2 RBD to Covid19 patients. Improvement of the clinical course 28 days after the start of treatment will be evaluated.
Detailed Description The pandemic caused by the new coronavirus has generated a situation unprecedented in recent history, with several million infected and hundreds of thousands of deaths. This disease is easily transmissible by air. Although a high percentage of cases present mild clinical presentation, approximately 15% of patients present moderate to severe cases and 5% require critical care, with respiratory assistance and a high risk of mortality. No effective therapies for the treatment or prevention of SARS.CoV2 have been identified yet. Preliminary evidence indicates that passive immunotherapy with convalescent plasma could alter the clinical course of this infection in a favorable manner. This strategy, even if confirmed as successful, requires voluntary donation by patients who have recovered, not all of whom are eligible as donors, since the antibody response varies in magnitude in different patients. This adaptive stage II/III study aims to analyze the efficacy and safety of passive immunotherapy by administering a purified Fab fraction of equine hyperimmune serum (INM005) generated from antigenic stimulation with the SARS-CoV2 RBD protein, with the objective of neutralizing the interaction of SARS-CoV-2 with its cellular receptor, thus preventing the multiplication of the virus. The safety of this type of equine hyperimmune sera has already been demonstrated in previous and ongoing protocols with a biologically equivalent product against the E. Coli shiga toxin to treat patients with Hemolytic Uremic Syndrome (CT-INM004-01 and CT-INM004-02). In the present study, eligible patients will with moderate to severe symptoms of COVID-19 that require hospitalization will receive two 4 mg/kg doses of INM005, two days apart, with the aim of improving the clinical course of COVID-19 28 days after the start of treatment with the study drug.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
This study will be an adaptive phase 2/3 investigation. First, 12 subjects will be randomly assigned to receive 1 of the 2 treatment regimens (study drug or placebo) in a 1:1 ratio. After the first 6 subjects have been enrolled and have completed 24 hours post treatment of 2nd dose, the IDMC will review the safety data and will inform whether to continue with staggered enrollment. Randomization ratio for subjects in the following stage will be 1:1. The independent data monitoring committee (IDMC) will review safety data after 12, 24, 48 and 96 patients have been enrolled in each arm. The study will then enroll a total of 121 patients in each arm. An interim analysis will be performed after 80% of recruitment has been reached (n=194). The IDMC will analyze the rate of events in the group under "standard of care".
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
A Double-blind, Placebo-controlled, sealed-envelope based. Access to unblinded interim results will be limited to the DMC and unblinded statistician
Primary Purpose: Treatment
Condition  ICMJE Covid19
Intervention  ICMJE
  • Drug: INM005
    The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
  • Drug: Placebo
    Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study Arms  ICMJE
  • Active Comparator: Active
    Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
    Intervention: Drug: INM005
  • Placebo Comparator: Placebo
    Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 30, 2020)
242
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 30, 2020
Actual Primary Completion Date November 23, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects of both sexes aged 18 to 79 years of age
  2. SARS-CoV-2 infection confirmed by PCR for virus detection
  3. Patients with moderate or severe disease by NIH definition, which requires hospitalization.
  4. Acceptance to participate in the study by the signature of the informed consent by a subject or their relative, if applicable
  5. Be within 10 days of the onset of symptoms at the time of the Screening visit according to a case definition from the National Ministry of Health
  6. Female patients of child-bearing age with negative pregnancy test

Exclusion Criteria:

  1. Patients who have received treatment with plasma from COVID-19 convalescents.
  2. Patients who are participating in other therapeutic clinical trials
  3. Patients who require mechanical respiratory assistance or are hospitalized in the ICU at the time of the screening visit.
  4. History of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses.
  5. Pregnant or breastfeeding women
  6. Patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease
  7. Patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 79 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04494984
Other Study ID Numbers  ICMJE CT-INM005-01
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Inmunova S.A.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Inmunova S.A.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Santiago Sanguineti, Ph.D. Inmunova S.A.
PRS Account Inmunova S.A.
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP